Igniting Hope for Tumor Immunotherapy: Promoting the "Hot and Cold" Tumor Transition. (September 2022)

• Record Type: Journal Article
• Authors: Wei, Chen; Ma, Yichao; Wang, Fei; Liao, Yiqun; Chen, Yuji; Zhao, Bin; Zhao, Qi; Wang, Daorong; Tang, Dong
• Is Part Of: Clinical medicine insights. Oncology. Volume 16(2022)
• Publication Date: 2022-09
• Subjects: cold tumor -- immunity therapy -- tumor microenvironment -- hot tumor -- immune checkpoint inhibitors; Oncology -- Periodicals; 616.994005
• DOI: 10.1177/11795549221120708
• Languages: English
• ISSNs: 1179-5549

Abstract

The discovery of immune checkpoint inhibitors (ICIs) has ushered a new era for immunotherapy against malignant tumors through the killing effects of cytotoxic T lymphocytes in the tumor microenvironment (TME), resulting in long-lasting tumor suppression and regression. Nevertheless, given that ICIs are highly dependent on T cells in the TME and that most tumors lack T-cell infiltration, promoting the conversion of such immunosuppressive "cold" tumors to "hot" tumors is currently a key challenge in tumor immunotherapy. Herein, we systematically outlined the mechanisms underlying the formation of the immunosuppressive TME in cold tumors, including the role of immunosuppressive cells, impaired antigen presentation, transforming growth factor-β, STAT3 signaling, adenosine, and interferon-γ signaling. Moreover, therapeutic strategies for promoting cold tumors to hot tumors with adequate T-cell infiltration were also discussed. Finally, the prospects of therapeutic tools such as oncolytic viruses, nanoparticles, and photothermal therapy in restoring immune activity in cold tumors were thoroughly reviewed.